These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37673125)

  • 21. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
    Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
    Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
    BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
    Dytfeld D; Wróbel T; Jamroziak K; Kubicki T; Robak P; Walter-Croneck A; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Lahoud OB; Zonder JA; Griffith K; Stefka A; Major A; Derman BA; Jakubowiak AJ
    Lancet Oncol; 2023 Feb; 24(2):139-150. PubMed ID: 36642080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
    Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
    Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
    Touzeau C; Perrot A; Hulin C; Manier S; Macro M; Chretien ML; Karlin L; Escoffre M; Jacquet C; Tiab M; Leleu X; Avet-Loiseau H; Jobert A; Planche L; Corre J; Moreau P
    Blood; 2024 May; 143(20):2029-2036. PubMed ID: 38394666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp.
    Zhou Q; Wen J; Xu F; Yue J; Zhang Y; Su J; Liu Y
    Technol Cancer Res Treat; 2024; 23():15330338241252605. PubMed ID: 38759699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
    Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
    Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
    PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
    Venner CP; Duggan P; Song K; Reece D; Sharma S; Su J; Jimenez-Zepeda VH; McCurdy A; Louzada M; Mian H; Sebag M; White D; Stakiw J; Kotb R; Aslam M; Reiman A; Gul E; Chu MP; Bergstrom D; LeBlanc R
    Transplant Cell Ther; 2024 Sep; 30(9):889-901. PubMed ID: 38971462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
    Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW
    J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
    Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
    Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
    Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
    Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
    Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
    Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
    Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.